- Home
- JRS vs RCEL Comparison
JRS vs RCEL Comparison
Compare JRS & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- RCEL
- Stock Information
- Founded
- JRS 2001
- RCEL 2020
- Country
- JRS United States
- RCEL United States
- Employees
- JRS N/A
- RCEL N/A
- Industry
- JRS Finance/Investors Services
- RCEL Medical/Dental Instruments
- Sector
- JRS Finance
- RCEL Health Care
- Exchange
- JRS Nasdaq
- RCEL Nasdaq
- Market Cap
- JRS 267.5M
- RCEL 308.6M
- IPO Year
- JRS N/A
- RCEL N/A
- Fundamental
- Price
- JRS $8.53
- RCEL $8.65
- Analyst Decision
- JRS
- RCEL Buy
- Analyst Count
- JRS 0
- RCEL 5
- Target Price
- JRS N/A
- RCEL $18.00
- AVG Volume (30 Days)
- JRS 86.6K
- RCEL 255.8K
- Earning Date
- JRS 01-01-0001
- RCEL 02-13-2025
- Dividend Yield
- JRS 8.87%
- RCEL N/A
- EPS Growth
- JRS N/A
- RCEL N/A
- EPS
- JRS N/A
- RCEL N/A
- Revenue
- JRS N/A
- RCEL $60,040,000.00
- Revenue This Year
- JRS N/A
- RCEL $40.30
- Revenue Next Year
- JRS N/A
- RCEL $53.22
- P/E Ratio
- JRS N/A
- RCEL N/A
- Revenue Growth
- JRS N/A
- RCEL 32.24
- 52 Week Low
- JRS $5.95
- RCEL $7.51
- 52 Week High
- JRS $8.00
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- JRS 46.97
- RCEL 30.98
- Support Level
- JRS $8.14
- RCEL $8.53
- Resistance Level
- JRS $8.70
- RCEL $9.42
- Average True Range (ATR)
- JRS 0.19
- RCEL 0.70
- MACD
- JRS 0.03
- RCEL -0.45
- Stochastic Oscillator
- JRS 67.24
- RCEL 2.48
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.